CRBP
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.08
−3.32%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
Market Cap
$214.30M
MomentumView details →
1D Return
−3.32%
YTD Return
+38.21%
RSI (14)
63.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
Market Cap
$214.30M
RSI (14)
63.7
MomentumView details →
1D Return
−3.32%
YTD Return
+38.21%
SummaryUpdated Jun 1, 2026
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a biopharmaceutical company founded in 2009 and headquartered in Norwood, Massachusetts. The company went public in October 2014 and focuses on developing innovative immune modulators for treating immuno-oncology and fibrosis diseases. Corbus operates as a clinical-stage biotechnology company, meaning it is primarily engaged in research and development activities rather than commercial product sales, with multiple drug candidates in various stages of clinical trials.
Similar companies
Latest newsMore news →
Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $35.0 million for Q2 2026, with a net loss per share of $1.81.30d agoThe U.S. Food and Drug Administration cleared Corbus Pharmaceuticals to initiate its registrational study TEMPO-1 of CRB-701 in patients with second-line oropharyngeal squamous cell carcinoma.39d ago